Catequentinib
Non-Small Cell Squamous Lung Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
52 Active assets in the Non-Small Cell Squamous Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BBB |
Serplulimab Shanghai Henlius Biotech | Phase 3 | BB |
Pembrolizumab Shanghai Henlius Biotech | Phase 3 | BB |
Cis-Diamminedichloroplatinum Ii Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BB |
Docetaxel Shanghai Henlius Biotech | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →